NLTX News and Press, Neoleukin Therapeutics Inc. From 07/23/23

NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Denbury Inc. (NYSE: DEN)'s sale to ...

NEW YORK, NY / ACCESSWIRE / July 21, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ:FRG)'s ...

2023-07-18 06:52:20 ET Clinical-stage company, Neurogene and Neoleukin Therapeutics ( NASDAQ: NLTX ) to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including ...

Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approxi...

2023-04-19 04:04:42 ET Summary Neoleukin Therapeutics is a failed biopharma that recently laid off the majority of its workforce and announced a strategic review. The company currently trades at a wide 36% discount to its estimated net cash upon strategic review conclusion. Wh...

2023-03-09 07:26:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday! Moving stocks this morning are earnings reports, clinical trial re...

2023-03-09 02:46:49 ET Biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, Neoleukin Therapeutics ( NASDAQ: NLTX ) to reduce workforce by ~70%. The company expects this reduction in force to be completed ...

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in ...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of th...